AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

NZ sharemarket enjoys good week with fourth gain
Markets Market close

NZ sharemarket enjoys good week with fourth gain

The S&P/NZX 50 Index closed at 11,938.08, up 64.04 points or 0.54%.

Graham Skellern 03 May 2024
BHP CEO flies to South Africa to push $65.4 billion takeover
Markets

BHP CEO flies to South Africa to push $65.4 billion takeover

The executives have already begun conversations with key stakeholders.

Bloomberg 03 May 2024
Rakon shareholder wants light shed on $400m bid
Markets

Rakon shareholder wants light shed on $400m bid

US giant Skyworks could be Rakon's new owner. One shareholder wants it to confirm.